Paul A. Harmon
Princeton University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul A. Harmon.
International Journal of Cancer | 1997
Amarnath Sharma; Eric Mayhew; Lois E. Bolcsak; Christopher Cavanaugh; Paul A. Harmon; Andrew S. Janoff; Ralph J. Bernacki
Although the current clinical formulation of paclitaxel (Taxol®) is an important new anti‐cancer agent, it has significant side effects, some of which are related to its formulation in Cremophor/ethanol, Paclitaxel is difficult to formulate for i.v. administration because of its poor aqueous solubility. Here, we report the therapeutic effects of 2 liposome formulations of paclitaxel against human ovarian A121 tumor growing as an s.c. xenograft in athymic nude mice. The liposome formulations used were ETL and TTL, which have 1 or 3 lipid components, respectively. TTL was used as a reconstituted lyophilate or as a stable aqueous suspension. ETL was used as a reconstituted lyophilate only. Both paclitaxel‐liposome formulations were much better tolerated than Taxol® after i.v. or i.p. administration. The acute reactions seen after Taxol® administration did not occur when paclitaxel‐liposome formulations were administered. All ETL and TTL preparations significantly delayed A121 tumor growth similarly to Taxol at equivalent doses and schedules. Based on pharmacokinetic data, it is possible that paclitaxel rapidly dissociates from ETL or TTL after i.v. administration and distributes in a manner similarly to Taxol. ETL and TTL formulations may be useful clinically not only for eliminating toxic effects of the Cremophor/ethanol vehicle but also for allowing alterations in route and schedule of drug administration. Int. J. Cancer, 71:103–107, 1997.
Biochimica et Biophysica Acta | 1997
Walter Perkins; Xingong Li; James L. Slater; Paul A. Harmon; Patrick L. Ahl; Sharma R. Minchey; Sol M. Gruner; Andrew S. Janoff
We have examined the calorimetric behavior of large liposomes consisting of symmetric saturated chain phosphatidylcholines. Most notably, for systems made in solutions containing solute (e.g., NaCl, glucose, etc.) there was an additional major endotherm just below the main phase transition temperature. The new endotherm was found to represent a population of lipid whose main phase transition was shifted to lower temperature due to an induced osmotic stress across the membrane. Absent for isoosmotic systems, the osmotic stress was created when the liposome internal volume decreased, a consequence of the Lbeta (gel) to Pbeta (rippled) phase transition. That is, rippling of the membrane caused vesicle volume to decrease (> or = 28%) and because the free flow of water outward was restricted by solute, an osmotic gradient was created where none had existed before. The distribution of enthalpy between the new shifted Tm and the expected Tm correlated with the percent of lipid in the outer bilayer and it was concluded that only the outer bilayer sensed the induced stress. Internalized liposome structures were shielded, thus explaining the persistence of the expected Tm in preparations made in solute. The shift in Tm (deltaTm) was discrete and linearly dependent upon lipid chain length for the PC series di-17:0 (deltaTm approximately 1.4 degrees C) through di-20:0 (deltaTm approximately 0.6 degrees C), suggesting a structural change (i.e., lipid packing/orientation) was involved. Although freeze-fracture electron microscopy of stressed and unstressed bilayers revealed no differences in ripple periodicity there were differences in surface features and in vesicle shape. The fact that this phenomenon has gone unnoticed for MLVs is probably due to the fact that these systems are known to exclude solute and thus exist under osmotic compression.
Archive | 1996
Eric Mayhew; J. Craig Franklin; Suresh Bhatia; Paul A. Harmon; Andrew S. Janoff
Analytical Biochemistry | 1997
Paul A. Harmon; Donna Cabral-Lilly; Robert A. Reed; Frank P. Maurio; J. Craig Franklin; Andrew S. Janoff
Pda Journal of Pharmaceutical Science and Technology | 2003
Robert A. Reed; Paul A. Harmon; Denise Manas; Walter Wasylaschuk; Chris Galli; Ryan Biddell; Paul A. Bergquist; William A. Hunke; Allen C. Templeton; Dominic Ip
Archive | 1996
Eric Mayhew; J. Craig Franklin; Suresh Bhatia; Paul A. Harmon; Andrew S. Janoff
Archive | 1997
Eric Mayhew; J. Craig Franklin; Suresh Bhatia; Paul A. Harmon; Andrew S. Janoff
Archive | 1996
Paul A. Harmon; Donna Cabral-Lilly; J. Craig Franklin; Robert A. Reed; Andrew S. Janoff
Archive | 2006
Yu Lu; William E. Bowen; Robert A. Reed; Allen C. Templeton; Paul A. Harmon; Lee Klein
Archive | 1996
Eric Mayhew; J. Craig Franklin; Suresh Bhatia; Paul A. Harmon; Andrew S. Janoff